Skip to content
‹ Back to IndustriesSciences

Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley sees 39% downside

Wall Street analysts are divided on Circle's valuation prospects. TD Cowen has rated Circle as a buy with a target price of $82, indicating optimism in its potential growth. Meanwhile, Morgan Stanley has significantly lowered its target to $38, questioning the utility of stablecoins.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · · Circle Internet GroupStablecoinsUsdcFintech
Share
Listen to the audio brief

Key facts, context, and what it means.

AUDIO
0:00—
Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley sees 39% downside

Key takeaways

01

TD Cowen set Circle's target price at $82, signaling expected growth.

02

Morgan Stanley reduced its target for Circle to $38, citing doubts about stablecoin use.

03

There is a significant split among analysts regarding Circle's financial outlook.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Two major Wall Street firms looked at Circle Internet Group this week and reached almost opposite conclusions. TD Cowen initiated coverage of the stablecoin issuer on August 3 with a buy rating and a price target of $82, implying 31% upside from its prior close, according to CNBC. Morgan Stanley, in the same period, downgraded the stock to underweight and cut its price target from $106 to $38, a move that implies 39% downside. The gap between those two targets is $44 per share, and the debate underneath it matters to any enterprise team currently evaluating stablecoin-based payments or treasury infrastructure.

The bull case: platform evolution beyond reserve income

TD Cowen analyst Bryan Bergin framed Circle not as a single-product stablecoin issuer but as an emerging financial infrastructure platform, citing growth in USDC circulation, expanding high-margin fee-based revenues, and the optionality embedded in its Arc product line, as reported by CNBC. His core argument is that consensus estimates undervalue Circle's trajectory toward a platform spanning payments, treasury, tokenized real-world assets, interoperability, and developer services.

For enterprise buyers, that framing has operational weight. If Circle succeeds in building durable, fee-based revenue streams on top of USDC, the infrastructure becomes stickier and less dependent on interest-rate environments that have already begun to compress reserve income. A platform model also means more integration surface area: APIs, developer tooling, and cross-border settlement rails that procurement and treasury teams can plug into existing workflows.

The $44-per-share gap between TD Cowen's and Morgan Stanley's Circle targets is not just a stock call, it is a direct read on how much of stablecoin volume will ever convert into durable commercial payment economics.

The bear case: volume does not equal utility

Morgan Stanley analyst James Faucette made the counter-argument on data grounds, drawing on McKinsey estimates that show roughly $35 trillion in adjusted stablecoin volume, of which only approximately $390 billion represents identifiable payments, as reported by CNBC. That is roughly 1% of adjusted activity. The rest is crypto trading and transfer volume, which generates transaction throughput but not the recurring commercial transaction economics that would offset pressure on Circle's reserve-income model.

Faucette acknowledged growth in cross-border B2B payments and consumer remittances, including stablecoin-linked card spending, but argued those use cases have not yet produced the durable balances or repeating transaction revenue needed to compensate if reserve yields continue to fall, according to CNBC. That is a meaningful distinction for any enterprise treasury team using USDC for cross-border settlement: the underlying issuer's financial resilience is partly a function of whether payment use cases scale fast enough to replace interest income.

Stablecoin volume: total vs. identifiable payments (McKinsey estimate, 2026)
McKinsey, via CNBC / Morgan Stanley research note · © MarketScaleDownload chart

Regulatory stall adds a third variable

Circle shares have dropped 21% in 2026, tracking a broader crypto pullback that has seen Bitcoin lose 28% of its value year-to-date, per CNBC. Part of the stock's pressure comes from legislative uncertainty around the Clarity Act, a bill designed to define regulatory boundaries for the crypto industry that has stalled in Congress despite White House support for its passage.

For compliance and procurement leaders, the Clarity Act's fate is more than a stock catalyst. Without it, enterprise legal teams lack the clear jurisdictional framework needed to sign off on large-scale stablecoin payment programs. Vendors pitching USDC-based treasury or settlement solutions are effectively asking buyers to commit to infrastructure whose regulatory treatment remains unsettled. That creates real contractual and audit exposure that procurement teams cannot ignore.

Broader analyst sentiment on Circle reflects the same uncertainty. LSEG data cited by CNBC shows that 16 of the 30 analysts covering the company rate it a hold or sell, while the remaining 14 rate it a buy or strong buy, a nearly even split on a stock that has been public for less than a full year.

What this means for your team

  • Pressure-test reserve-income sensitivity: any stablecoin infrastructure vendor whose revenue depends heavily on interest earned on reserves faces margin risk if rates move or regulatory requirements on reserve composition tighten. Ask vendors for fee-based revenue as a percentage of total revenue and how that share is trending.
  • Separate volume from payment utility: McKinsey's figure of $390 billion in identifiable payments out of $35 trillion in total stablecoin volume is the sharpest benchmark available right now. Use it to challenge vendor claims about 'stablecoin adoption' and focus RFPs on documented B2B payment transaction economics, not raw volume.
  • Monitor the Clarity Act actively: if the legislation passes, it materially reduces legal risk for enterprise stablecoin programs and likely accelerates vendor investment in compliance tooling. Assign a compliance team member to track its Congressional status as a formal procurement gate.
  • Build evaluation criteria that survive either scenario: given the 31%-vs.-39% divergence in analyst targets, enterprise teams should avoid single-vendor dependency on USDC infrastructure until the platform's revenue diversification is demonstrably underway. Maintain parallel banking and payment rails while pilots run.

Featured companies

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, the programme logged 133 follow-up visits against 17 treatments; with roughly 15 years of twice-yearly checkups per patient, the follow-up load is likely to keep growing even if new treatments stay flat.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

Nov 16, 2026

Two photonic AI components reach outside testers—limited access

Two photonic AI components reach outside testers—limited access

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and Kopin’s expansion adds another competitor for photonics technicians in Massachusetts.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly’s Goochland County site is designed to make APIs and finished medicines on one campus. Virginia Business reported the first building is expected to open in 2030.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512